AstraZeneca today presented data from the AURA3 trial that is supportive of TAGRISSO ® (osimertinib) potentially becoming the new standard of care for second-line treatment of patients with epidermal growth factor...

AstraZeneca and its hematology Center of Excellence, Acerta Pharma, today announced preliminary results from the Phase I/II ACE-CL-001 clinical trial of acalabrutinib in subsets of patients with two difficult-to-treat...

AstraZeneca today announced data from the second season of its SENTINEL1 study, the largest study ever to examine laboratory-confirmed respiratory syncytial virus hospitalizations (RSVH) among US preterm infants 29-35 weeks...

AstraZeneca's Lynparza significantly delayed the recurrence of tumors in patients with ovarian cancer compared to a placebo, according to results from a phase III study announced by the company Wednesday.

AstraZeneca today announced positive results from the Phase III SOLO-2 trial designed to determine the efficacy of LYNPARZA TM (olaparib) tablets (300mg twice daily) as a monotherapy for the maintenance treatment of...